Moreover, notable advancements in breast cancer therapy have been achieved through the utilization of dual-specific antibodies targeting transforming growth factor-β (TGFR-β) and PD-L1, exemplified by YM101 and BiTP treatment (22, 23). Here, CD274 is linked to breast carcinoma.